Journal of General Internal Medicine

, Volume 1, Issue 3, pp 183–195 | Cite as

The evaluation and treatment of hypercholesterolemia in primary care practice

  • Wayne L. Peters
  • Allan H. Goroll
Clinical Review


Cholesterol Cocoa Butter Gemfibrozil Coronary Heart Disease Risk Probucol 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Castelli WP. Epidemiology of coronary heart disease: The Framingham Study. Am J Med 1984;76(2A):4–12CrossRefPubMedGoogle Scholar
  2. 2.
    Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis 1978;31:201–306CrossRefGoogle Scholar
  3. 3.
    Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham Study. Ann Intern Med 1979;90:85–91CrossRefPubMedGoogle Scholar
  4. 4.
    Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA 1984;251:351–74CrossRefGoogle Scholar
  5. 5.
    Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080–6Google Scholar
  6. 6.
    Peters WL, Hegsted DM, Leaf A. Lipids, nutrition, and coronary heart disease. In: Curfman GD, Leaf A, eds. Preventive cardiology and cardiac rehabilitation. Cardiol Clin North Am 1985;3:179–91Google Scholar
  7. 7.
    Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med 1983;309:288–96CrossRefPubMedGoogle Scholar
  8. 8.
    Grundy SM. Hypertriglyceridemia: mechanisms, clinical significance, and treatment. Med Clin North Am 1982;66:519–35CrossRefPubMedGoogle Scholar
  9. 9.
    Gotto AM, Phil D, Gorry A, et al. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. Circulation 1977;56:875–83CrossRefPubMedGoogle Scholar
  10. 10.
    Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predicators of the severity of coronary artery disease in men and women. Circulation 1985;71:881–8CrossRefPubMedGoogle Scholar
  11. 11.
    Sigurdsson G, Nicoll A, Lewis B. Conversion of very low density lipoprotein to low density lipoprotein: a metabolic study of apolipoprotein B kinetics in human subjects. J Clin Invest 1975;56:1481–90CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholesterolemia: implications for pathogenesis and therapy. Med Clin North Am 1982;66:335–62CrossRefPubMedGoogle Scholar
  13. 13.
    Kesaniemi YA, Grundy SM. Significance of low density lipoprotein production in the regulation of plasma cholesterol level in man. J Clin Invest 1982;70:13–22CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369–77, 420–5CrossRefPubMedGoogle Scholar
  15. 15.
    Jenkins PJ, Harper RW, Nestel PJ. Severity of coronary atherosclerosis related to lipoprotein concentration. Br Med J 1978;2:388–91CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich Jr PO. Association of coronary atherosclerosis with hyperapobetalipoproteinemia. Proc Natl Acad Sci USA 1980;77:604–8CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977;62:707–12CrossRefPubMedGoogle Scholar
  18. 18.
    Miller NE, Hammett F, Saltissi S, et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoprotein. Br Med J 1981;282:1741–4CrossRefGoogle Scholar
  19. 19.
    Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJT. Apoliprotein A-1 as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983;309:387–9CrossRefGoogle Scholar
  20. 20.
    Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983;67:730–4CrossRefPubMedGoogle Scholar
  21. 21.
    Kannel WB, Doyle JT, Ostfeld AM, et al. Optimal resources for primary prevention of atherosclerotic diseases. Circulation 1984;70:155A-205ACrossRefGoogle Scholar
  22. 22.
    Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr 1965;17:281–95PubMedGoogle Scholar
  23. 23.
    Keys A, Anderson JT, Grande F. Prediction of serum cholesterol responses of man to changes in fats in the diet. Lancet 1957;2:959–66CrossRefGoogle Scholar
  24. 24.
    Cortese C, Levy Y, Janus ED, et al. Modes of action of lipid-lowering diets in man: studies of apolipoprotein B kinetics in relation to fat consumption and dietary fatty acid composition. Eur J Clin Invest 1983;13:79–85CrossRefPubMedGoogle Scholar
  25. 25.
    Mattson FM, Grundy SM. Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J Lipid Res 1985;26:194–202PubMedGoogle Scholar
  26. 26.
    Goodnight SH, Harris WS, Connor WE, Illingworth DR. Polyunsaturated fatty acids, hyperlipidemia and thrombosis. Arteriosclerosis 1982;2:87–113CrossRefPubMedGoogle Scholar
  27. 27.
    Fischer S, Weber PC. Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 1984;307:165–8CrossRefPubMedGoogle Scholar
  28. 28.
    Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Draper HH (ed), Advanced nutrition research. Vol 3. New York: Plenum Press; 1980:1–22Google Scholar
  29. 29.
    Kromhout D, Bosschieter EB, Coulander CDL. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205–9CrossRefPubMedGoogle Scholar
  30. 30.
    Phillipson BE, Harris WS, Connor WE, Harris WS, Illingworth R. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985;312:1210–6CrossRefPubMedGoogle Scholar
  31. 31.
    Grundy SM, Bilheimer D, Blackburn H, et al. Rationale of the dietheart statement of the American Heart Association. Report of Nutrition Committee. Circulation 1982;165(4):839A-54AGoogle Scholar
  32. 32.
    Mattson FH, Erickson BA, Kligman AM. Effect of dietary cholesterol on serum cholesterol in men. Am J Clin Nutr 1972;25:589–94PubMedGoogle Scholar
  33. 33.
    Schonfeld G, Patsch W, Rudel LL, Nelson C, Epstein M, Olson RE. Effects of dietary cholesterol and fatty acids on plasma lipoproteins. J Clin Invest 1982;69:1072–80CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Packard CJ, McKinney L, Carr K, Shepard J. Cholesterol feeding increases low density lipoprotein synthesis. J Clin Invest 1983;72:45–51CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Connor WE, Lin DS. The effect of shellfish in the diet upon the plasma lipid levels in humans. Metabolism 1982;31:1046–51CrossRefPubMedGoogle Scholar
  36. 36.
    Anderson JW, Story L, Sieling B, Chen W-JL, Petro MS, Story J. Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. Am J Clin Nutr 1984;40:1146–55CrossRefPubMedGoogle Scholar
  37. 37.
    Kesaniemi YA, Grundy SM. Increased low density lipoprotein production associated with obesity. Arteriosclerosis 1983;3:170–7CrossRefPubMedGoogle Scholar
  38. 38.
    Keys A (ed): Coronary heart disease in seven countries. Circulation 1970;1:(suppl 1):1-1–1-211Google Scholar
  39. 39.
    Kagan A, Harris BR, Winkelstein W Jr, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary, and biochemical characteristics. J Chronic Dis 1974;27:345–64CrossRefPubMedGoogle Scholar
  40. 40.
    Wynder EL, Lemon FR. Cancer, coronary artery disease and smoking: a preliminary report on differences in incidences between Seventh-Day Adventists and others. Calif Med 1958;89:267–72PubMedPubMedCentralGoogle Scholar
  41. 41.
    Shekelle RB, Shryock AM, Paul O, et al. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric Study. N Engl J Med 1981;304:65–70CrossRefPubMedGoogle Scholar
  42. 42.
    Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention and the incidence of coronary heart disease. Lancet 1981;2:1303–10CrossRefPubMedGoogle Scholar
  43. 43.
    Canner PL. Longterm mortality in Coronary Drug Project (CDP) patients. Circulation 1985;71:413ACrossRefGoogle Scholar
  44. 44.
    Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the National Heart, Lung and Blood Institute Type II Coronary Intervention Study. Circulation 1984;69:313–24CrossRefPubMedGoogle Scholar
  45. 45.
    Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis: The Leiden Intervention Trial. N Engl J Med 1985;312:805–11CrossRefPubMedGoogle Scholar
  46. 46.
    Albers JJ, Warnick R, Johnson N, et al. Quality control of plasma high-density lipoprotein cholesterol measurement methods. Circulation 1980;62(Suppl IV):9–17Google Scholar
  47. 47.
    Frederickson DS, Levy RI, Lees RS. Fat transport in lipoproteins—an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34–44CrossRefGoogle Scholar
  48. 48.
    Wyngaarden JB, Frederickson DS, Goldstein JL, Brown MS. Disorders of lipoprotein and lipid metabolism. Part 4. In: Stanbury JB, et al (eds). The metabolic basis of inherited disease. Ed. 5. New York: McGraw-Hill, 1983;587–747Google Scholar
  49. 49.
    Shaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. N Engl J Med 1985;312:1300–10CrossRefGoogle Scholar
  50. 50.
    Connor WE, Connor SL. The dietary treatment of hyperlipidemia. Med Clin North Am 1982;66:485–518CrossRefPubMedGoogle Scholar
  51. 51.
    Crimmins CJ, Braunstein NS, Sonnenberg L, Peters WL. Nutritional strategies in heart disease prevention. In: Leaf A. ed. Preventive cardiology and cardiac rehabilitation. Cardiol Clin North Am 1985;3:193–202Google Scholar
  52. 52.
    Ehnholm C, Huttunen JK, Pietinen P, et al. Effect of diet on serum lipoproteins in a population with a high risk of coronary heart disease. N Engl J Med 1982;307:850–5CrossRefPubMedGoogle Scholar
  53. 53.
    Wolf RN, Grundy SM. Influence of weight reduction on plasma lipoproteins in obese patients. Arteriosclerosis 1983;3:160–9CrossRefPubMedGoogle Scholar
  54. 54.
    Wood PD, Haskell WL, Blair SN, et al. Increased exercise level and plasma lipoprotein concentrations: a one-year, randomized, controlled study in sedentary, middle-aged men. Metabolism 1983;32:31–9CrossRefPubMedGoogle Scholar
  55. 55.
    Haskell WL, Camargo Jr C, Williams PT, et al. The effect of cessation and resumption of moderate alcohol intake on serum high-density-lipoprotein subfractions. N Engl J Med 1984;310:805–10CrossRefPubMedGoogle Scholar
  56. 56.
    Treatment of hypertriglyceridemia. JAMA 1984;251:1196–200Google Scholar
  57. 57.
    Witzum JL, Schonfeld G. Carbohydrate diet-induced changes in very low density lipoprotein composition and structure. Diabetes 1978;27:1215–29CrossRefGoogle Scholar
  58. 58.
    Shepherd J, Packard CJ, Bicker S, Vietch Lawrie TD, Morgan HG. Cholestyramine promotes receptor mediated low density lipoprotein catabolism. N Engl J Med 1980;302:1219–22CrossRefPubMedGoogle Scholar
  59. 59.
    Grundy SM, Mok HYI, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22:24–36PubMedGoogle Scholar
  60. 60.
    Shepard J, Packard CJ, Patsch JR, Gotti Jr AM, Taunton OD. Effects of nicotinic acid therapy on plasma high density subfraction and composition and on apolipoprotein A metabolism. J Clin Invest 1979;63:858–67CrossRefGoogle Scholar
  61. 61.
    Hoeg JM, Maher MB, Bou E, et al. Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin. Circulation 1984;70:1004–11CrossRefPubMedGoogle Scholar
  62. 62.
    Kesaniemi YA, Grundy SM. Turnover of low density lipoproteins during inhibition of cholesterol absorption by neomycin. Arteriosclerosis 1984;4:41–8CrossRefPubMedGoogle Scholar
  63. 63.
    Schade RWB, van’t Laar A, Majoor CLH, Jansen AP. A comparative study of the effects of cholestyramine and neomycin in the treatment of Type II hyperlipoproteinemia. Acta Med Scand 1976;199:175–80CrossRefPubMedGoogle Scholar
  64. 64.
    Dujovne CA, Krehbiel P, Decoursey S, et al. Probucol with colestipol in the treatment of hypercholesterolemia. Ann Intern Med 1984;100:477–82CrossRefPubMedGoogle Scholar
  65. 65.
    Glueck CJ. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Ann Intern Med 1982;96:475–82CrossRefPubMedGoogle Scholar
  66. 66.
    Havel RJ, Kane JP. Therapy of hyperlipidemic states. Annu Rev Med 1982;33:417–33CrossRefPubMedGoogle Scholar
  67. 67.
    Tobert JA, Bell GD, Birtwell J, et al. Cholesterol lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J Clin Invest 1982;69:913–9CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern Med 1984;101:598–604CrossRefPubMedGoogle Scholar
  69. 69.
    Nessim SA, Chin, HP, Alaupovic P, Blankenhorn DH. Combined therapy of niacin, colestipol, and fat-controlled diet in men with coronary bypass: effect on blood lipids and apolipoproteins. Arteriosclerosis 1983;3:568–73CrossRefPubMedGoogle Scholar
  70. 70.
    Kane JP, Malloy MJ, Tun P, et al. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 1981;304:251–8CrossRefPubMedGoogle Scholar
  71. 71.
    Kensaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984;251:2241–6CrossRefGoogle Scholar
  72. 72.
    Wolfe BM, Kane JP, Havel RJ, Brewster HP. Mechanism of the hypolipidemic effect of clofibrate in postabsorptive man. J Clin Invest 1973;52:2146–59CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–81CrossRefGoogle Scholar
  74. 74.
    Committee of Principle Investigators: A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978;40:1069–118CrossRefGoogle Scholar

Copyright information

© Society for Research and Education in Primary Care Internal Medicine 1986

Authors and Affiliations

  • Wayne L. Peters
    • 1
  • Allan H. Goroll
  1. 1.Denver

Personalised recommendations